Long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers

AIDS Research and Human Retroviruses

Volumn 24, Issue 11, 2008, Pages 1445-1448

  Silbermann, Benjamin ^a   Tod, Michel ^a,g   Desaint, Corinne ^a   Pialoux, Gilles ^b   Petitprez, Karine ^a   Slama, Laurence ^b   Poncelet, Hubert ^a   Moreau, Corinne ^c   Mazarin, Veronique ^c   Heshmati, Farad ^a   Salmon Ceron, Dominique ^a,d   Guillet, Jean Gerard ^e   Launay, Odile ^a,d,f  

^a Pôle de Médecine ^*  (France)

^b HÔPITAL TENON   (France)

^c SANOFI PASTEUR   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CNRS   (France)

^f INSERM   (France)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; HIV RECOMBINANT CANARYPOX VIRUS CONSTRUCT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN GP 160; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT VACCINE;

ADULT; ARTICLE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SERODIAGNOSIS; SEROLOGY; BLOOD; IMMUNOLOGY; MIDDLE AGED; TIME;

ADULT; AIDS VACCINES; FEMALE; FOLLOW-UP STUDIES; HIV ANTIBODIES; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; VACCINES, SYNTHETIC;

EID: 57049162024     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0107     Document Type: Article

References (15)

1. Girard MP, Osmanov SK, and Kieny MP: Review of vaccine research and development: The human immunodeficiency virus (HIV). Vaccine 2006;24(19):4062-4081.
2. Ackers ML, Parekh B, Evans T, Berman P, et al.: Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis 2003;187(6):879-886.
3. Gorse GJ, Frey SE, Patel G, et al.: Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network. Vaccine 1994;12(10):912-918.
4. Graham BS, Gorse GJ, Schwartz DH, et al.: Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. J Infect Dis 1994;170(4):782-786.
5. Durier C, Launay O, Meiffredy V, et al.: Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006;20(7):1039-1049.
6. Centers for Disease Control and Prevention: Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep 1989;38(Suppl 7):1-17.
7. Tableman M and Kim JS: Survival Analysis Using S. CRC. Chapman and Hall, New York, 2004, pp. 55-94.
8. Spiegelhalter D, Thomas A, and Best N: WinBUGS 1.3 Manual. MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK, 2000.
9. Evans TG, Frey S, Israel H, et al.: Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. HIV Vaccine Trials Network (HVTN 803). Vaccine 2004;22(20):2626-2630.
10. Wang S, Kennedy JS, West K, et al.: Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008;26(8):1098-1100. Epub January 10, 2008.
11. Schwartz DH, Laeyendecker OB, Arango-Jaramillo S, et al.: Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR. Lancet 1997;350(9073):256-259.
12. Sheon AR, Wagner L, McElrath MJ, et al.: Preventing discrimination against volunteers in prophylactic HIV vaccine trials: Lessons from a phase II trial. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19(5):519-526.
13. Allen M, Israel H, Rybczyk K, et al.: Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses 2001;17(8):667-674.
14. Belshe RB, Clements ML, Keefer MC, et al.: Interpreting HIV serodiagnostic test results in the 1990s: Social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group. Ann Intern Med 1994;121(8):584-589.
15. Launay O, Durier C, Desaint C, Silbermann B, Lelièvre JD, Slama L, Morineau Le Houssine P, Poizot-Martin I, Cuzin L, Doré V, Spire B, Linard F, Rieux V, de Saunière A, Guillet JG, Lévy Y, and Aboulker JP, for the ANRS COHVAC Study Group: A prospective study for evaluating long term safety of preventive HIV-1 vaccine candidates: The ANRS COHVAC Cohort. AIDS Vaccine 2007; August 20-23, 2007, Seattle, WA.